American Drug Costs Set to Surge $19B Under New EU Import Tariffs
Your medicine cabinet just got more expensive thanks to Uncle Sam’s new trade appetite. Starting next month, a new EU-US trade agreement is set to slap a 15% tariff on imported European medicines, potentially adding up to $19B in costs for the pharmaceutical industry. These expenses will likely trickle down to American consumers, ending decades of duty-free pharmaceutical imports that helped keep medicine costs in check.
- Europe manufactures the active ingredients for 43% of brand-name drugs consumed in America, with Ireland alone exporting $50B worth of pharma products to US shores annually.
- The tariffs will affect popular medications, including Pfizer’sPFE Viagra, Johnson & Johnson’sJNJ cancer drugs, and Novo Nordisk’sNVO Ozempic and Wegovy.
Bitter pill to swallow: RSM US chief economist Joe Brusuelas warned, “The cost of imported drugs is about to become more expensive for all Americans.” While certain generic medications received exemptions, the deal’s rollout next month will test if pharma firms absorb the hit or pass along price hikes to patients already struggling with healthcare affordability. Insurance providers in New York, Oregon, and Maryland have already signaled premium increases tied to anticipated tariff impacts, hinting that Americans might feel the impact beyond the pharmacy counter.